Premium
Sarepta Therapeutics Inc New (SRPT)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-03-11 | Mr. Ian Michael EstepanPresident & COO | -1,10k | 18,68k | Sale to Issuer | 17,03 | 201,98k | -0,54% |
| 2026-03-11 | Mr. Ryan H. WongExec. VP & CFO | -256,00 | 4,36k | Sale to Issuer | 17,03 | 135,06k | -0,19% |
| 2026-03-11 | Dr. Louise R. Rodino-KlapacPresident of Research & Development and Technical Operations | -948,00 | 16,14k | Sale to Issuer | 17,03 | 225,32k | -0,42% |
| 2026-03-12 | Dr. Stephen L. MayoIndependent Director | -7,24k | 123,21k | Vente | 17,02 | 1,77k | -80,40% |
| 2026-03-11 | Cristin RothfussInitié | -974,00 | 16,59k | Sale to Issuer | 17,03 | 137,54k | -0,70% |
| 2026-03-09 | Mr. Ryan H. WongExec. VP & CFO | -275,00 | 4,66k | Sale to Issuer | 16,95 | 135,32k | -0,20% |
| 2026-03-09 | Cristin RothfussInitié | -830,00 | 14,07k | Sale to Issuer | 16,95 | 138,52k | -0,60% |
| 2026-03-09 | Dr. Louise R. Rodino-KlapacPresident of Research & Development and Technical Operations | -1,40k | 23,71k | Sale to Issuer | 16,95 | 226,27k | -0,61% |
| 2026-03-09 | Mr. Ian Michael EstepanPresident & COO | -1,62k | 27,44k | Sale to Issuer | 16,95 | 203,08k | -0,79% |
| 2026-03-02 | Cristin RothfussInitié | -408,00 | 6,61k | Sale to Issuer | 16,20 | 139,35k | -0,29% |
| 2026-03-02 | Mr. Ryan H. WongExec. VP & CFO | -450,00 | 7,29k | Sale to Issuer | 16,20 | 135,60k | -0,33% |
| 2026-03-01 | Mr. Ian Michael EstepanPresident & COO | 3,95k | 0,00 | Derivative Exercise and Retained Stock | - | 204,70k | 1,97% |
| 2026-03-01 | Mr. Ian Michael EstepanPresident & COO | -4,18k | 67,65k | Derivative Exercise and Sale | 16,20 | 204,70k | - |
| 2026-03-01 | Dr. Louise R. Rodino-KlapacPresident of Research & Development and Technical Operations | 3,64k | 0,00 | Derivative Exercise and Retained Stock | - | 227,67k | 1,62% |
| 2026-03-01 | Dr. Louise R. Rodino-KlapacPresident of Research & Development and Technical Operations | -4,49k | 72,66k | Derivative Exercise and Sale | 16,20 | 227,67k | - |
| 2026-02-26 | Mr. Ian Michael EstepanPresident & COO | 7,45k | 102,14k | Derivative Exercise and Retained Stock | 13,71 | 200,75k | 3,85% |
| 2026-01-29 | Dr. Claude NicaiseIndependent Non-Employee Director | -6,78k | 50,99k | Derivative Exercise and Sale | 13,71 - 21,23 | 29,15k | - |
| 2026-01-29 | Dr. Claude NicaiseIndependent Non-Employee Director | 3,72k | 51,00k | Derivative Exercise and Retained Stock | 13,71 | 29,15k | 14,63% |
| 2026-01-27 | Dr. M. Kathleen Behrens WilseyIndependent Chairwoman | 4,01k | 54,92k | Derivative Exercise and Retained Stock | 13,71 | 205,10k | 1,99% |
| 2026-01-27 | Dr. M. Kathleen Behrens WilseyIndependent Chairwoman | -6,49k | 54,94k | Derivative Exercise and Sale | 13,71 - 22,17 | 205,10k | - |
| 2025-12-16 | Mr. Ian Michael EstepanPresident & COO | -13,19k | 294,20k | Vente | 22,31 | 193,30k | -6,39% |
| 2025-12-01 | Mr. Ryan H. WongExec. VP & CFO | -158,00 | 3,31k | Sale to Issuer | 20,96 | 136,05k | -0,12% |
| 2025-11-28 | Cristin RothfussInitié | -229,00 | 4,84k | Sale to Issuer | 21,12 | 139,76k | -0,16% |
| 2025-11-17 | Dr. Louise R. Rodino-KlapacPresident of Research & Development and Technical Operations | -4,58k | 84,40k | Sale to Issuer | 18,42 | 224,03k | -2,00% |
| 2025-07-31 | Mr. Ryan H. WongExec. VP & CFO | -327,00 | 5,37k | Sale to Issuer | 16,42 | 17,33k | -1,85% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
